66.03

0.92% 0.595

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $66.03, with a volume of 374.20K. It is up +0.92% in the last 24 hours and up +11.41% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Previous Close:

$65.44

Open:

$65.32

24h Volume:

374.20K

Relative Volume:

0.54

Market Cap:

$2.84B

Revenue:

$535.08M

Net Income/Loss:

$-48.27M

P/E Ratio:

-58.26

EPS:

-1.1335

Net Cash Flow:

$-31.54M

1W Performance:

+7.81%

1M Performance:

+11.41%

6M Performance:

-17.32%

1Y Performance:

+60.49%

1-Day Range:

$64.50

$67.00

1-Week Range:

$56.51

$67.00

52-Week Range:

$38.51

$85.25

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1097)

Industry

Biotechnology (615)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

370

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

TARS's Discussions on Twitter

Compare TARS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TARS Tarsus Pharmaceuticals Inc	66.07	2.71B	535.08M	-48.27M	-31.54M	-1.1335
VRTX Vertex Pharmaceuticals Inc	527.99	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	647.54	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	926.19	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.63	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.17	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Resumed	Oppenheimer	Outperform
Dec-09-25	Initiated	Barclays	Overweight
Nov-20-25	Initiated	Mizuho	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-27-25	Resumed	H.C. Wainwright	Buy
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

Jul 01, 2026

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Yahoo Finance

Jul 01, 2026

Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme - Benzinga

Jul 01, 2026

TARS Stock Drops 10% Following Short Position Announcement - GuruFocus

Jul 01, 2026

Culper Research Says We Are Short Tarsus Pharmaceuticals - TradingView

Jul 01, 2026

Jun 29, 2026

Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Tarsus (TARS) director awarded RSUs and options for 6,254 shares - Stock Titan

Jun 29, 2026

Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants - Stock Titan

Jun 29, 2026

Tarsus Pharmaceuticals (TARS) grants director RSUs and stock options - Stock Titan

Jun 29, 2026

Equity awards grant Tarsus (TARS) director RSUs and stock options - Stock Titan

Jun 29, 2026

Tarsus (TARS) director receives new RSU and stock option awards - Stock Titan

Jun 29, 2026

Tarsus (TARS) director Wendy Yarno receives RSU and option grants as board pay - Stock Titan

Jun 29, 2026